Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Nifurtimox

FDA-approved product (tablet, oral), marketed as Lampit.

Registered studies
19
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Nifurtimox
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • American trypanosomiasis
  • Chagas disease
  • Leishmaniasis
  • Trypanosomiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nitrofuran derivatives
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01CC01

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA44.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli42.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis78.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Nifurtimox in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.9 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Nifurtimox with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health

    NCT05477953 · start 2026-12-31

    Registered record
    Registry ID
    NCT05477953
    Conditions
    Chagas Disease
    Interventions
    Nifurtimox (BAYA2502)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-12-31
    Completion
    2032-01-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionNifurtimox (BAYA2502)
    PhaseNot recorded
    Registry statusNot yet recruiting

  • New Therapies and Biomarkers for Chagas Infection

    NCT03981523 · start 2019-12-18

    Registered record
    Registry ID
    NCT03981523
    Conditions
    Trypanosoma Cruzi Infection; Chagas Disease
    Interventions
    Benznidazole; Nifurtimox
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2019-12-18
    Completion
    2024-05-31
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrypanosoma Cruzi Infection; Chagas Disease
    InterventionBenznidazole; Nifurtimox
    PhasePhase 2
    Registry statusCompleted

  • Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study

    NCT03334838 · start 2019-06-10

    Registered record
    Registry ID
    NCT03334838
    Conditions
    Chagas' Disease
    Interventions
    Nifurtimox (Lampit, BAYA2502)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-06-10
    Completion
    2020-01-29
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas' Disease
    InterventionNifurtimox (Lampit, BAYA2502)
    PhasePhase 1
    Registry statusCompleted

  • Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

    NCT03784391 · start 2018-12-14

    Registered record
    Registry ID
    NCT03784391
    Conditions
    Chagas' Disease
    Interventions
    Lampit (Nifurtimox, BAYA2502)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-12-14
    Completion
    2020-04-06
    Enrolment
    3,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas' Disease
    InterventionLampit (Nifurtimox, BAYA2502)
    PhaseNot recorded
    Registry statusCompleted

  • Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation

    NCT03708133 · start 2018-12-05

    Registered record
    Registry ID
    NCT03708133
    Conditions
    Bioequivalence
    Interventions
    Nifurtimox (Lampit, BAYA2502)_Test; Nifurtimox (Lampit, BAYA2502)_Reference
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-12-05
    Completion
    2019-06-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBioequivalence
    InterventionNifurtimox (Lampit, BAYA2502)_Test; Nifurtimox (Lampit, BAYA2502)_Reference
    PhasePhase 1
    Registry statusCompleted

  • Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg

    NCT03350295 · start 2018-06-14

    Registered record
    Registry ID
    NCT03350295
    Conditions
    Chagas Disease
    Interventions
    Nifurtimox (Lampit, BAYA2502)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-06-14
    Completion
    2018-12-14
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionNifurtimox (Lampit, BAYA2502)
    PhasePhase 1
    Registry statusCompleted

  • Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment

    NCT04274101 · start 2018-06-01

    Registered record
    Registry ID
    NCT04274101
    Conditions
    Chagas Disease
    Interventions
    Clinical Manifestations; Serologic response; Direct method; Adverse events
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2018-06-01
    Completion
    2025-02-01
    Enrolment
    900

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionClinical Manifestations; Serologic response; Direct method; Adverse events
    PhaseNot recorded
    Registry statusUnknown

  • A Study to Learn How Well Nifurtimox Works and How Safe it is in Children Aged 0 to 17 Years With Chagas' Disease, an Inflammatory, Infectious Disease Caused by the Parasite Trypanosoma Cruzi

    NCT02625974 · start 2016-01-27

    Registered record
    Registry ID
    NCT02625974
    Conditions
    Chagas Disease
    Interventions
    Nifurtimox (Lampit, BAYA2502); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-01-27
    Completion
    2021-08-10
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionNifurtimox (Lampit, BAYA2502); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients

    NCT02606864 · start 2015-12

    Registered record
    Registry ID
    NCT02606864
    Conditions
    Chagas Disease
    Interventions
    Nifurtimox (BAYa2502)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-12
    Completion
    2016-08
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionNifurtimox (BAYa2502)
    PhasePhase 1
    Registry statusCompleted

  • CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)

    NCT02369978 · start 2015-08

    Registered record
    Registry ID
    NCT02369978
    Conditions
    Chagas Disease
    Interventions
    Nifurtimox; Benznidazole; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Unknown
    Start
    2015-08
    Completion
    2019-02
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionNifurtimox; Benznidazole; Placebo
    PhasePhase 2 / Phase 3
    Registry statusUnknown

  • Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients

    NCT01927224 · start 2013-11

    Registered record
    Registry ID
    NCT01927224
    Conditions
    Chagas Disease
    Interventions
    Nifurtimox (BAYa2502) (4 x 30 mg tablet); Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water); Nifurtimox (BAYa2502) (120 mg tablet)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-11
    Completion
    2014-09
    Enrolment
    37

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease
    InterventionNifurtimox (BAYa2502) (4 x 30 mg tablet); Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water); Nifurtimox (BAYa2502) (120 mg tablet)
    PhasePhase 1
    Registry statusCompleted

  • Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease

    NCT01744405 · start 2012-12

    Registered record
    Registry ID
    NCT01744405
    Conditions
    Chagas Disease; Lactation
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-12
    Completion
    2015-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChagas Disease; Lactation
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2

    NCT01685827 · start 2012-10

    Registered record
    Registry ID
    NCT01685827
    Conditions
    Human African Trypanosomiasis (HAT); Sleeping Sickness
    Interventions
    Fexinidazole; Nifurtimox; Eflornithine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2017-04-26
    Enrolment
    394

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman African Trypanosomiasis (HAT); Sleeping Sickness
    InterventionFexinidazole; Nifurtimox; Eflornithine
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Clinical Study to Assess the Tolerability, Feasibility and Effectiveness of Nifurtimox and Eflornithine (NECT) for the Treatment of Trypanosoma Brucei Gambiense Human African Trypanosomiasis (HAT) in the Meningo-encephalitic Phase

    NCT00906880 · start 2009-04

    Registered record
    Registry ID
    NCT00906880
    Conditions
    Human African Trypanosomiasis
    Interventions
    Nifurtimox-Eflronithine Combination Treatment (NECT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2013-01
    Enrolment
    630

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman African Trypanosomiasis
    InterventionNifurtimox-Eflronithine Combination Treatment (NECT)
    PhasePhase 4
    Registry statusCompleted

  • Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

    NCT00601003 · start 2008-01-14

    Registered record
    Registry ID
    NCT00601003
    Conditions
    Neuroblastoma; Medulloblastoma
    Interventions
    Nifurtimox; Cyclophosphamide; Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2008-01-14
    Completion
    2022-10-28
    Enrolment
    112

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeuroblastoma; Medulloblastoma
    InterventionNifurtimox; Cyclophosphamide; Topotecan
    PhasePhase 2
    Registry statusCompleted